Skip to main content
ADHDnotepad
Section 1

Overview

Medication class

Stimulant: methylphenidate hydrochloride, a direct dopamine and noradrenaline reuptake inhibitor. Not a . Not a releasing agent.

When it's prescribed

First-line for adults with ADHD in the UK, per NICE guidelines. IR is often the starting point when flexible dosing or shorter coverage windows are preferred.

Typical duration

3–5 hours. Two or three doses per day for all-day coverage.

Available strengths

Ritalin 10mg; Medikinet 5mg, 10mg, 20mg; generic methylphenidate 5mg, 10mg, 20mg. Your prescriber will advise the right brand and strength for you.

Key advantages

  • Fast onset: you'll notice quite quickly whether it's working
  • Short duration: more flexible: you decide which parts of the day you're medicated
  • If side effects occur, they wear off with the dose: not an all-day problem
  • Multiple strengths available for precise dose adjustment
  • Well-established and widely studied: the most researched ADHD medication
  • Tablets can be split in half if needed
  • Lower cost; generic widely available

Key cautions

  • Multiple daily doses: the lunchtime dose is commonly forgotten; plan for it actively
  • Rebound effect: possible mood or energy dip as each dose clears
  • Alcohol has a specific harmful interaction with methylphenidate: do not drink
  • Tics: strong evidence of a link: personal or family history needs to be discussed with your prescriber
  • Last dose must be at least 4 hours before bedtime
  • Heart rate and blood pressure are monitored throughout treatment
  • Schedule 2 Controlled Drug: keep it secure; never share it
Section 2

How it works

Methylphenidate works differently from Elvanse. There's no prodrug step, no conversion process, nothing that needs to happen before it's active. You swallow the tablet and it's in your system within about 20–30 minutes.

Once it reaches your brain, it blocks two types of molecular transport channels: the dopamine transporter (DAT) and the noradrenaline transporter (NET). These channels normally mop up dopamine and noradrenaline from the gap between nerve cells and recycle them back in. Methylphenidate blocks that recycling, so both chemicals stay available longer in the places where they work.

This isn't the same as releasing dopamine: that's what amphetamines do. Methylphenidate simply stops the brain from clearing it too quickly.

Dopamine is your brain's "is this worth doing?" signal. Low dopamine makes starting tasks genuinely hard, even important ones. It's why motivation evaporates the moment something stops being new.

Noradrenaline is your brain's signal-to-noise filter. It helps the planning part of your brain (the prefrontal cortex) focus on what matters and filter out everything else. Low noradrenaline is why you drift, why distractions feel impossible to ignore, why you keep forgetting what you were doing mid-task.

Methylphenidate brings both up to a more useful level.

Once absorbed, methylphenidate is cleared by your liver and broken down into an inactive substance. This happens fairly quickly: that's why each dose lasts only a few hours rather than all day. The effect building and fading is predictable and repeatable. Each new dose brings things back up.

Methylphenidate hydrochloride (MPH) is a piperidine derivative and central nervous system stimulant. It acts as a selective dopamine and noradrenaline reuptake inhibitor (DNRI) through high-affinity blockade of the dopamine transporter (DAT) and noradrenaline transporter (NET). Unlike amphetamines, it does not act as a releasing agent and does not significantly affect serotonin systems.

Mechanism: MPH binds competitively to DAT and NET, reducing reuptake of dopamine and noradrenaline from the synaptic cleft. This increases extracellular monoamine availability in prefrontal cortex and striatum: circuits implicated in working memory, attention regulation, and inhibitory control.

Pharmacokinetics (IR formulation): Tmax approximately 1–2 hours. Duration of action 3–5 hours. Oral bioavailability approximately 22–25% due to extensive first-pass metabolism. Primarily metabolised by CES1A1 esterase to ritalinic acid (inactive). Not significantly metabolised by CYP450.

Alcohol interaction (CES1A1 pathway): Alcohol competitively inhibits CES1A1, impairing methylphenidate clearance and causing plasma levels to exceed expected range. Co-administration also permits trans-esterification of methylphenidate by alcohol to form ethylphenidate: a novel psychoactive substance with stimulant and potentially harmful properties. This interaction is specific to methylphenidate and does not apply to amphetamine-class ADHD medications.

Generic prescribing note: Methylphenidate IR is typically prescribed generically as 'methylphenidate hydrochloride' in the UK, not by brand name. Patients may receive Ritalin, Medikinet, or generic formulations interchangeably on a given prescription.

Section 3

How to take it

When to take it: building your daily dose schedule

Unlike long-acting formulations, methylphenidate IR needs to be taken more than once a day to cover your whole day. Most people take two or three doses: • First dose: At breakfast (or within 30 minutes of waking) • Second dose: At lunchtime: approximately 4–5 hours after your first dose • Third dose (if prescribed): Mid-afternoon: your prescriber will give you a specific time The lunchtime dose is the most commonly forgotten one. Set an alarm. Put a dose in your desk drawer. Link it to something you already do at lunch. This isn't a moral failing: forgetting a mid-day dose is exactly the kind of thing ADHD makes difficult.

The 4-hour rule

Your last dose of the day should be at least 4 hours before you plan to go to sleep. Methylphenidate that's still active when you're trying to sleep will keep you awake. If you usually sleep at 11pm, your last dose should be no later than 7pm.

With or without food?

Either works: there's no requirement to take methylphenidate with food. That said: • Taking it with or after food helps reduce nausea and stomach discomfort, especially in the first few doses. • Food delays the onset by about an hour. That's fine: not a problem, just something to know. If the first dose makes your stomach uncomfortable, try taking it with a small amount of food from the start.

Missed your lunchtime dose?

• It's still early afternoon → take it when you remember • It's already late afternoon → skip it. Do not take a double dose. A late dose will keep you awake tonight. The rule is: skip it rather than take it late.

Do I need to take it every day?

Not necessarily. Because each dose is independent, some people choose not to take methylphenidate on days with lower demands: weekends, holidays, or quieter periods. This is much easier to manage with IR than with long-acting formulations. Discuss this option with your prescriber, particularly around monitoring weight and how well things go on non-medication days.

Stopping methylphenidate

Methylphenidate IR doesn't need a formal gradual dose reduction to stop. However, if you've been taking it for a long time or at a higher dose, stopping suddenly may cause a few days of low mood or fatigue as your body adjusts: and your ADHD symptoms will return. Speak to your prescriber before stopping rather than stopping without warning: the higher the dose and the longer the use, the more worthwhile it is to plan the stop with them.

What not to combine with methylphenidate

Tell your prescriber and pharmacist about everything: including supplements and anything over-the-counter. The most important: • Alcohol: Do not drink. See the How It Works section for why this is more than a general caution. • MAOIs (a type of antidepressant): absolute no: cannot be taken within 14 days of stopping an MAOI. Risk of dangerous blood pressure spike. • Blood pressure medications: Methylphenidate may work against them. • Certain antipsychotics and antidepressants (including fluoxetine, aripiprazole): These can slow down how your body clears methylphenidate, increasing its levels in your system. • Warfarin, phenytoin, certain antidepressants: Methylphenidate may affect how these medicines work in your body. • Cough and cold remedies: Some contain ingredients that affect blood pressure. Check before buying. • Before any surgery: Tell your anaesthetist or surgical team you take methylphenidate. Don't take it on the day of surgery if the anaesthetic uses halogenated agents.

Drug testing and driving

Drug testing: Methylphenidate may give a positive result. If you're subject to workplace, sporting, or any other drug testing, tell the relevant people you take a prescribed controlled drug. Carry your prescription or a letter from your prescriber. Driving: You're protected under the statutory defence as long as methylphenidate was prescribed to you for ADHD, you're taking it exactly as directed, and it's not actually affecting your ability to drive safely. Don't drive in the first few days of starting or after a dose change: until you know how this dose affects you.

Pregnancy and breastfeeding

If you're pregnant, think you might be pregnant, or are planning a pregnancy, speak to your prescriber before continuing methylphenidate. Based on BUMPS/UKTIS (January 2023): The evidence is uncertain; there may be a small increased risk of miscarriage and possibly a small increase in the risk of heart-related birth defects. But the evidence isn't clear, and most babies are unaffected. Taking methylphenidate during pregnancy may slow the baby's growth: extra growth scans in later pregnancy may be offered. Don't stop suddenly without speaking to your midwife, GP, or specialist: a planned reduction is safer. Breastfeeding: Methylphenidate is considered the stimulant of choice while breastfeeding (Breastfeeding Network, April 2025). Milk levels are very low. Use the lowest effective dose and time your dose after a feed where possible. Monitor your baby for irritability, sleep changes, or feeding difficulties. You don't need to stop breastfeeding because of methylphenidate: discuss the specifics with your prescriber. If you're a man: current evidence doesn't suggest any risk to a baby if the father takes methylphenidate.

Section 4

What to expect: week by week

First dose

The on/off pattern

Most people notice something within the first dose. Focus feels more accessible. Starting a task that normally feels impossible becomes a bit less so. The mental noise drops. Because IR wears off in a few hours, the 'on' feeling is fairly clear: and so is when it stops. This makes IR easier to assess than long-acting formulations. You'll know whether it's working.

Days 1–7

Early adjustment

The most common things in the first week: reduced appetite while the dose is active; possible mild headache (drink more water); possible stomach discomfort with the first few doses (take with food to reduce this); maybe feeling a little wired or over-focused at the peak of the first dose or two; a dip in mood or energy as each dose wears off: especially in the late afternoon. This is the rebound effect. It's normal. Note when it happens.

Weeks 1–4

Titration and settling in

Your prescriber will increase your dose gradually over these weeks. Small steps, one at a time. This isn't because the medication 'isn't working': it's finding the right dose for your brain with the fewest side effects. Most early side effects settle by weeks 2–3. Watch for: how long each dose lasts; when the rebound effect happens; what time your last dose needs to be for sleep not to be disrupted; whether you're eating enough despite appetite suppression.

At target dose

Established effect

Once you've found the right dose and schedule, the aim is consistent, manageable coverage across your working day. It shouldn't feel like a different you: more like things that were always difficult becoming slightly more accessible. If the dose feels off (too much, too little, wearing off too soon, causing rebound), say so at your next review. Dose adjustments are common and normal.

Long-term

Ongoing treatment

Methylphenidate IR doesn't have to be forever. If you take it for more than a year, your prescriber may suggest a treatment break: a short period without medication to check whether it's still needed and still working as expected. This is standard practice, not a sign anything is wrong.

Section 5

Side effects & what helps

All expanded by default: tap a category to collapse it. Most of these ease in the first 1–2 weeks.

Reduced appetite

Very common (more than 1 in 10; ~22% in a large 52-week study)

What helps

This happens while each dose is active and eases between doses and in the evening. Eat breakfast before or with your first dose; this is the most important meal of the day on methylphenidate. Appetite tends to return between doses and in the evening: use those windows for proper meals. Talk to your prescriber if weight loss is becoming significant.

Weight loss

Common (~6% in the 52-week study)

What helps

Some weight change is common. Your prescriber will monitor this at every review.

Difficulty falling asleep

Very common

What helps

This almost always comes down to timing: a dose taken too late is still active when you're trying to sleep. Follow the 4-hour rule (last dose at least 4 hours before bed). If you're still struggling, try shifting your last dose 30–60 minutes earlier. Avoid caffeine after 2pm. If sleep problems haven't improved after 2–3 weeks of timing adjustments, tell your prescriber.

Anxiety, agitation, restlessness, irritability

Common (agitation ~11%, restlessness ~10% in the 52-week study)

What helps

Note when it happens. During the peak of a dose → may be dose-related. In the late afternoon/evening → likely the rebound effect as the last dose clears. Good sleep, regular meals, and hydration all help. Reducing caffeine helps with jitteriness.

Rebound effect (mood dip as doses wear off)

Common

What helps

A predictable dip in mood, energy, or focus as each dose clears. Most noticeable in the late afternoon or early evening. Track when it happens in relation to your doses and tell your prescriber. Timing adjustments, a small additional dose, or switching to a long-acting formulation are all options.

Feeling emotionally flat or unlike yourself

Less common

What helps

Some calming is expected and often welcome. If it feels like your personality has disappeared or you feel muted, raise it; this is usually dose-related and adjustable.

Depressed mood

Common (~5% in the 52-week study)

What helps

Contact your prescriber before your next review if you notice persistent low mood, emotional flatness, or any thoughts of self-harm.

Mania (feeling unusually euphoric or uninhibited)

Rare

What helps

Contact your prescriber promptly. Tell your prescriber before starting methylphenidate if you have a history of bipolar disorder.

Headaches, particularly in the first 1–2 weeks

Very common

What helps

Almost always dehydration. Stimulants reduce your sense of thirst; you stop drinking without noticing. Drink more water: aim for 6–8 glasses a day. Set reminders if needed. Paracetamol is safe alongside methylphenidate.

Dry mouth

Very common (~15% in the 52-week study)

What helps

Sip water regularly through the day. Sugar-free gum or mints stimulate saliva.

Nausea, stomach pain, diarrhoea, stomach discomfort

Very common

What helps

Common with the first few doses. Take the tablet with food; this significantly reduces stomach side effects. Usually settles within 1–2 weeks.

Teeth grinding (bruxism)

Common

What helps

Some people clench or grind their teeth while on methylphenidate. Let your dentist know. Note whether it happens every day or only on higher-dose days. Jaw awareness exercises and reducing caffeine can help with daytime clenching. Mention it at your next review if it's uncomfortable or affecting your teeth.

Mildly increased heart rate

Common (~6% in study)

What helps

A small rise in heart rate is an expected effect of stimulant medication. It's not dangerous in people with a healthy heart. Your prescriber monitors this at reviews.

Palpitations (noticing your heartbeat, or it feeling irregular)

Common (up to 1 in 10; ~13% in the 52-week study)

What helps

Brief, mild awareness of your heartbeat: especially in the first few weeks: is normal. Reduce caffeine and stay hydrated. Contact your prescriber if your heart races or pounds at rest, or palpitations come with dizziness or breathlessness.

Elevated blood pressure

Common

What helps

Checked at every review. If you monitor at home, contact your prescriber if consistently above your baseline.

Chest pain

Uncommon

What helps

This is a serious side effect. See your prescriber promptly: do not wait for your next review.

Tics (repeated twitching or sounds)

Common/Very common (BNF)

What helps

The link between methylphenidate and tics is well established. If you have a personal or family history of tics or Tourette's syndrome, discuss this specifically with your prescriber before starting. If tics appear or get worse while you're taking methylphenidate, contact your prescriber; they don't always mean stopping the medication, but they do need assessing.

Restlessness, tremor, dizziness, feeling jittery

Common

What helps

Usually settle within the first few weeks. Dizziness: stay hydrated and don't drive while it's present. Jitteriness: reducing caffeine helps.

Excessive sweating

Common (~6% in the 52-week study)

What helps

Usually manageable. Mention at your next review if it's affecting daily life.

Hair loss

Common

What helps

Unusual hair loss or thinning is listed as a common side effect. Mention at your next review if you notice it.

Shortness of breath

Common

What helps

Mild breathlessness can occur. If significant, at rest, or combined with chest pain or palpitations: seek prompt medical attention.

Raynaud's phenomenon (fingers or toes going pale, numb, or cold in cold weather)

Very rare

What helps

Keep your hands and feet warm. Avoid handling frozen items without gloves. Reducing caffeine helps. Contact your prescriber if it's frequent or causing distress.

Changes in sex drive; erectile problems; prolonged erections

Rare / frequency not known

What helps

Discuss with your prescriber; you don't have to just put up with it. Prolonged erections lasting more than 2 hours (particularly if painful) should be reported promptly.

Blurred or double vision

Uncommon

What helps

Do not drive or operate machinery if this occurs.

Section 6

When to seek help

No action

Expected: keep going

Common in the first few weeks: no action usually needed

  • Reduced appetite while doses are active; appetite returning between doses and in the evening
  • Mild headache, particularly in week one
  • Dry mouth
  • Stomach discomfort in the first few doses
  • A mood or energy dip in the late afternoon as the last dose wears off: predictable and manageable
  • Brief, mild awareness of your heartbeat (not at rest, not painful)
  • Slightly better focus from the first dose: that's it working
Contact prescriber

Mention at your next review

Not urgent: but worth discussing at your next review

  • Sleep problems that haven't improved after 2–3 weeks of timing adjustments
  • Significant unintended weight loss, or consistently not eating enough
  • Feeling emotionally flat or unlike yourself
  • Persistent anxiety, agitation, or jitteriness
  • Rebound effect in the late afternoon or evening that's significantly affecting your mood, relationships, or quality of life
  • Blood pressure consistently higher than your baseline
  • Tics or twitching that are new or getting worse
  • Palpitations that are brief and mild but happening regularly
  • Fingers or toes going pale, numb, or blue in the cold
  • Persistent headaches beyond the first two weeks
  • Hair loss
Urgent

Contact your prescriber soon: don't wait for your next review

Do not wait for a routine appointment

  • Chest pain, at any time, including at rest
  • Racing, pounding, or irregular heartbeat at rest
  • Palpitations sustained, or coming with dizziness or shortness of breath
  • New or significantly worsening tics
  • New onset of low mood, severe anxiety, or thoughts of self-harm
  • Feeling paranoid, or seeing, hearing, or feeling things that aren't there
  • New or worsening mood swings, including feeling unusually high or uninhibited
  • Yellowing of skin or the whites of your eyes
  • Sudden weakness, numbness, difficulty speaking, or confusion; these may be signs of a stroke. Call 999 immediately. Do not wait for a prescriber callback.

What you can safely try while waiting for a review

  • Drink more water: dehydration makes almost every stimulant side effect worse
  • Take tablets with food if stomach side effects are the problem
  • Take the last dose earlier if sleep is being disrupted (follow the 4-hour rule)
  • Keep a brief daily note of symptoms, timing, and when they occur relative to your doses: invaluable at reviews
  • Reduce caffeine, especially after 2pm
  • Plan lower-demand activities in the late afternoon if the rebound effect is predictable
  • Eat properly: regular meals reduce the severity of mood-related side effects and rebound
  • Paracetamol is safe for headaches
  • If fingers or toes go pale or numb in the cold, keep your hands warm and mention it at your next review
Section 7

Frequently asked questions

Why can't I drink alcohol with methylphenidate?

This isn't just the usual 'stimulants and alcohol don't mix' warning. Methylphenidate has a specific chemical interaction with alcohol that other ADHD medications don't have. Two things happen: (1) Alcohol blocks the enzyme (CES1A1) that clears methylphenidate from your body: so more of it stays in your system at higher levels than intended. (2) Alcohol and methylphenidate can react in your liver to create a new substance called ethylphenidate. This doesn't happen with Elvanse or other ADHD medications. Ethylphenidate is active: and potentially harmful. The result is unpredictable. The advice isn't 'be careful with alcohol': it's 'don't drink while you're taking methylphenidate.'

What is the rebound effect?

As each dose of methylphenidate wears off, some people notice a dip: lower mood, irritability, low energy, or the feeling that ADHD symptoms are more intense than before. This tends to happen in the late afternoon or early evening when the last dose of the day is clearing. It's a recognised side effect of IR methylphenidate, and it's more noticeable with IR than with long-acting formulations because the medication clears faster. What can you do? Track when it happens and tell your prescriber. Timing adjustments or a small third dose sometimes solve it. If it's significantly affecting your life, discuss whether a long-acting formulation might work better.

I keep forgetting my lunchtime dose. What can I do?

Forgetting a mid-day dose is genuinely one of the challenges of IR methylphenidate: and it's exactly the kind of thing ADHD makes difficult. Some approaches that help: • Set a phone alarm every day at the same time • Keep a dose at work in a clearly marked container (in original packaging: required for Schedule 2 CDs) • Link dosing to something you already do at lunch: making tea, sitting down, checking your phone • Ask a colleague (if comfortable) to give you a nudge If compliance with multiple daily doses is consistently difficult, it's worth discussing whether a long-acting formulation would be more practical for your life.

Would a long-acting formulation work better for me?

Possibly. Long-acting methylphenidate (e.g. Medikinet XL, Equasym XL, Concerta XL) or a long-acting amphetamine (e.g. Elvanse) provides 8–14 hours of coverage from a single morning dose: no lunchtime dose, smoother wear-off, usually less rebound. IR is often the starting point because it's easy to assess and adjust. But many adults find long-acting formulations more practical for everyday life once the right medication is identified. This is a conversation worth having with your prescriber, especially if: the rebound effect is significantly affecting your evenings; you frequently forget the lunchtime dose; or your daily demands require consistent coverage well into the evening.

Will I become addicted to methylphenidate?

Physical dependence: where your body adapts to expect the medication: can develop with long-term use. But this is not the same as addiction. People with ADHD generally don't develop compulsive drug-seeking behaviour when taking prescribed methylphenidate at the right dose. The risk is associated with misuse at very high doses, not with therapeutic use. Take it only as prescribed and do not share it. If you have a history of alcohol or drug misuse, tell your prescriber before starting: it's relevant clinical information, not a reason to be refused medication.

Can I drink coffee while taking methylphenidate?

Caffeine adds to the stimulant effects; it can increase heart rate, anxiety, jitteriness, and sleep disruption. Many people find reducing caffeine (especially in the afternoon) makes a meaningful difference. If you notice more jitteriness, more anxiety, or worse sleep, try cutting caffeine before adjusting anything else.

Will methylphenidate show up on a drug test?

Yes; it can give a positive result for stimulants. If you're subject to workplace, sporting, or any other drug testing, tell the relevant people you take a prescribed controlled drug. Carry your prescription or a letter from your prescriber.

What if the medication wears off too quickly?

If you consistently find that the effect lasts significantly less than 3–5 hours, note the timing and tell your prescriber. Your prescriber may adjust the dose schedule, change the timing, add a dose, or discuss whether a long-acting formulation would provide better coverage. Do not adjust your dose yourself.

Do I need to take it every day?

Not necessarily. Because IR doses are independent, taking a break on lower-demand days (weekends, holidays) is more straightforward than with long-acting formulations. Some people find this works well; others prefer consistent daily use for a more stable baseline. Discuss what makes sense for your situation with your prescriber: especially around monitoring weight and how symptoms are on non-medication days.

What happens when I stop methylphenidate?

Methylphenidate IR doesn't require a formal gradual dose reduction. But if you've been taking it for a long time or at a higher dose, stopping suddenly may cause a few days of low mood or fatigue as your body adjusts: and your ADHD symptoms will return. The higher the dose and the longer the duration, the more worthwhile it is to plan the stop with your prescriber rather than stopping without warning.

What about methylphenidate and pregnancy?

Talk to your prescriber before becoming pregnant if possible, or as soon as you know you are pregnant. Based on BUMPS/UKTIS (January 2023): The evidence is uncertain. There may be a small increased risk of miscarriage and possibly a small increase in the risk of cardiac birth defects: but the evidence isn't clear and most babies are unaffected. Taking methylphenidate in pregnancy may slow the baby's growth. Extra growth scans in later pregnancy may be offered. Babies born after exposure near the end of pregnancy may have temporary withdrawal symptoms: jitteriness, difficulty sleeping, and breathing problems. These usually resolve within days. Don't stop suddenly without speaking to your midwife, GP, or specialist. A planned reduction is safer. Breastfeeding: Methylphenidate is the stimulant of choice while breastfeeding (Breastfeeding Network, April 2025). Milk levels are very low. You do not need to stop breastfeeding. Use the lowest effective dose, time your dose after a feed where possible, and monitor your baby for irritability, sleep changes, or feeding difficulties. If you're a man: current evidence doesn't suggest any risk to a baby if the father takes methylphenidate.

Does methylphenidate interact with antidepressants?

It depends on the type: • MAOIs: Absolute no: do not take methylphenidate within 14 days of stopping an MAOI. Risk of dangerous blood pressure spike. • Fluoxetine and certain others: These can slow down how your body clears methylphenidate, increasing its levels. Tell your prescriber. • Tricyclic antidepressants (TCAs): Methylphenidate may increase their levels in your blood. Always tell your prescriber and pharmacist about all medications you take.

My prescription says just 'methylphenidate': is that the same thing?

Yes. Methylphenidate hydrochloride is the active ingredient in Ritalin, Medikinet, and generic methylphenidate tablets. The brand name varies but the active ingredient is the same. Your prescriber may prescribe by brand or generically: ask if you're unsure what you're being prescribed.

Section 8

Ask your prescriber

Questions worth raising at your next review. You don't need to cover all of them: pick the ones that feel most relevant.

  • Are there any monitoring checks I'm due: blood pressure, pulse, weight?
  • How long does each dose seem to last? (Note the time you take each dose and when you notice it wearing off.)
  • Are you managing to take your lunchtime dose reliably? Are there practical barriers?
  • Are you noticing a rebound effect: a dip in mood, energy, or focus as doses wear off? When does it happen?
  • Are you noticing any side effects: and when do they occur relative to your dose schedule?
  • Is your appetite being significantly affected? Are you eating enough across the day?
  • Has your sleep changed since starting methylphenidate? Are you taking the last dose at least 4 hours before bed?
  • Have you noticed any mood changes: anxiety, low mood, emotional blunting, or irritability?
  • Have you noticed any changes in heart rate or blood pressure? (If you monitor at home.)
  • Are any of your other medicines interacting with methylphenidate?
  • Would it be worth discussing switching to a long-acting formulation: for better coverage and to reduce rebound?
  • Are you subject to drug testing at work or for sport?
  • Are you pregnant, planning a pregnancy, or has anything changed with contraception?
  • Do you have any questions about taking breaks from medication?
  • What would be the signs that methylphenidate IR isn't the right choice for me?
Section 9

For GPs & clinicians

For GPs and clinicians

Methylphenidate hydrochloride IR is licensed for ADHD in adults. It is a first-line stimulant per NICE NG87. IR is typically the starting formulation when flexible dosing, shorter coverage windows, or ease of dose assessment is preferred. Prescribed generically as 'methylphenidate hydrochloride' in most UK practices.

Start at 5mg 2–3 times daily. Titrate by 5–10mg increments at weekly intervals according to response and tolerability. Standard adult therapeutic range: 20–60mg/day in 2–3 divided doses. Maximum per BNF: 100mg/day. Doses should be at least 4 hours before bedtime to minimise sleep disruption.

Methylphenidate is primarily metabolised by CES1A1 to ritalinic acid. Alcohol competitively inhibits CES1A1, impairing clearance and causing plasma levels to exceed the therapeutic range. Co-administration also permits trans-esterification to ethylphenidate: a novel psychoactive substance with stimulant properties. This interaction is unique to methylphenidate and does not apply to amphetamine-class agents. Advise complete avoidance of alcohol; occasional social drinking (in the context of methylphenidate) should be declared and discussed; it is not simply an 'avoid excessive alcohol' caution.

MAOIs: absolute contraindication: hypertensive crisis risk; 14-day washout required. CYP450 inhibitors (fluoxetine, aripiprazole, risperidone): reduce MPH clearance, raising plasma levels: monitor and consider dose reduction. Antihypertensives: MPH may antagonise antihypertensive effects: monitor BP. Anticoagulants and anticonvulsants (warfarin, phenytoin, TCAs): MPH may inhibit metabolism: monitor levels. Anaesthetic agents: advise patients to withhold MPH on day of surgery if halogenated agents used.

Assess cardiovascular risk before initiating. Absolute contraindications include severe hypertension, heart failure, symptomatic coronary artery disease, arrhythmias, cardiomyopathy, and channelopathies. Obtain baseline BP and HR; monitor at each dose change and at least every 6 months at stable dose. Refer for cardiac evaluation if new cardiovascular symptoms emerge during treatment.

Tics are more common with methylphenidate than with lisdexamfetamine. Pre-existing tics or Tourette's syndrome are not absolute contraindications: individual assessment and monitoring is required. If tics develop or worsen during treatment, review the dose and consider switching to lisdexamfetamine, which has lower tic signal, or atomoxetine. Do not discontinue without assessment.

SmPC does not provide specific dose adjustment guidance for renal or hepatic impairment. For renal impairment: start low, go slow; closer monitoring recommended; document clinical decision. For hepatic impairment: prescriber should consider hepatic function before initiating and monitor more closely. Methylphenidate is primarily CES1A1-metabolised; hepatic function affects clearance.

Pregnancy (BUMPS/UKTIS January 2023): Evidence is uncertain. Possible small increased risk of miscarriage and cardiac defects; most babies unaffected. Monitor fetal growth. Standard anomaly scan appropriate. Do not stop abruptly: planned reduction with obstetric/psychiatric input. Manufacturer advises caution.

Breastfeeding (BfN April 2025): Methylphenidate is the stimulant of choice during breastfeeding. Milk levels are low and relative infant dose is small. No need to stop breastfeeding. Use lowest effective dose; time dose after a feed. Monitor infant for irritability, sleep disturbance, or feeding difficulties.

Note for GP letter (clinician-facing only): Methylphenidate may raise prolactin levels: relevant context for any breastfeeding concerns raised by the GP.

No mandatory taper for methylphenidate IR. However, if higher dose and/or longer duration of use, consider planned stopping with prescriber to mitigate discontinuation symptoms (low mood, fatigue, return of ADHD symptoms). These are readjustment effects, not physical withdrawal.

Switching to MR equivalences (SPS August 2025): Concerta XL 18mg ≈ 15mg IR total daily dose; Equasym XL 10mg ≈ 10mg IR total daily dose; Medikinet XL 10mg ≈ 10mg IR total daily dose. Detailed switching guidance on the MPH MR pages.

Standard NHS CD regulations apply: maximum 30 days' supply per prescription. Shared care arrangements vary by region; your GP and specialist will agree monitoring responsibilities. Baseline and ongoing cardiovascular monitoring is typically specialist-initiated but may be continued in primary care under a shared care agreement.

This guide is written for educational purposes and does not constitute medical advice. Always follow the guidance of your prescriber or pharmacist. If you have concerns about your medication, contact your clinical team.